Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting.

Esteban DaudénElena EscarioLuisa Martos-CabreraSusana ArmestoEnrique Herrera-AcostaDavid VidalEva VilarrasaRaquel RiveraPablo de la CuevaAntonio MartorellFerran BallescaIsabel Belinchón-RomeroGregorio CarreteroLourdes RodríguezAlberto Romero-MatéJ Pujol-MontcusíLaura SalgadoAntonio Sahuquillo-TorralbaPablo Coto-SeguraOfelia BaniandrésR FeltesJosep Riera-MonroigJesus GarridoMar Llamas-Velasco

Published in: International journal of dermatology (2024)

Off-label SEC-DR strategy was used in patients with sustained response to standard dose regimen; this strategy showed long-term efficacy without compromising treatment survival or worsening the safety profile while also being cost saving.

Keyphrases

healthcare
coronary artery disease
physical activity
clinical trial
cross sectional
rheumatoid arthritis
combination therapy
double blind
free survival
disease activity